The management of epilepsy in women of child-bearing age and the Australian experience of valproate in pregnancy.
Published opinion is reviewed and summarized with special reference to the teratogenic potential of the newer anticonvulsant drugs, treatment decisions and patient supervision. An Australian report covering a period of eight years, summarizing congenital malformations in births to patients whose treatment included sodium valproate (EpilimR) is presented against the background of the WHO report on valproate and pregnancy.